EP1133511B1 - Novel intermediates, process for preparing macrolide antibiotic agent therefrom - Google Patents

Novel intermediates, process for preparing macrolide antibiotic agent therefrom Download PDF

Info

Publication number
EP1133511B1
EP1133511B1 EP99958490A EP99958490A EP1133511B1 EP 1133511 B1 EP1133511 B1 EP 1133511B1 EP 99958490 A EP99958490 A EP 99958490A EP 99958490 A EP99958490 A EP 99958490A EP 1133511 B1 EP1133511 B1 EP 1133511B1
Authority
EP
European Patent Office
Prior art keywords
formula
oxime
erythromycin
compound
equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99958490A
Other languages
German (de)
French (fr)
Other versions
EP1133511A1 (en
Inventor
Tae Suk Lee
Chang Hyun Yoo
Kyoung Soo Kim
Hyun Suk An
Jung Young Kim
Wan Joo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemtech Research Inc
Hansol Chemience Co Ltd
Original Assignee
Chemtech Research Inc
Hansol Chemience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemtech Research Inc, Hansol Chemience Co Ltd filed Critical Chemtech Research Inc
Publication of EP1133511A1 publication Critical patent/EP1133511A1/en
Application granted granted Critical
Publication of EP1133511B1 publication Critical patent/EP1133511B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a novel process for the preparation of clarithromycin represented by formula (I), which has broad antimicrobial activity as a macrolide antibiotic agent, and a novel intermediate that can be used for its synthesis.
  • This process comprises protecting 3'-N,N-dimethylamino group and 2'-OH group of erythromycin 9-oxime derivative, wherein an OH group is protected, with a carbobenzyloxy(Cbz) group and then methylating the hydroxyl group at the 6 position of said compound (see Korean Patent Publication Nos. 91-5898 and 91- 7572).
  • this process has the disadvantages that an excess Cbz-Cl that is relatively expensive should be used, and even though the deprotection is carried out by the hydrogen reaction, this reaction is not completed on account of the catalytic poison.
  • This process comprises protecting 3'-N,N-dimethylamino group of erythromycin 9-oxime derivative, wherein an OH group is protected, with a quaternary salt of an identical group (for example, benzyl group)(see Korean Patent Publication No.91-2142). Since the deprotection in this process is also carried out by using hydrogen as in process 1, it has the disadvantage that the reaction is not completed on account of the catalytic poison as in Process 1.
  • This process may be represented by the following scheme:
  • This process comprises protecting an oxime of erythromycin 9-oxime derivative with a benzyl or ketal derivative, and protecting 2'-OH group and 4'-OH group of said compound with substituted silyl groups, and then methylating a 6-OH group of said compound, and finally deprotecting a protecting group of 9-oxime and trimethylsilyl group of said 2'-O- and 4"-O- groups of said compound simultaneously in a relatively short step to obtain the desired compound (see Korean Patent Publication Nos. 95-9367 and 96-434).
  • the 9-oxime derivative used in the trimethylsilylation of 2'-OH and 4'-OH groups should be used in the salt free form. This process is represented by the following scheme:
  • the yield of clarithromycin synthesized from an erythromycin A is about 45 to 50%.
  • a benzyl derivative is used to protect an oxime for the above reaction schemes, it is difficult to perform such lengthy reactions since the deprotection is carried out by using hydrogen.
  • Another shortcoming is that the ketal derivative, which is used to protect an oxime, has to be used excessively (with about 2 to 3 equivalents) and the total reaction time is rather lengthy. Despite of such shortcoming, the ketal derivative and trimethylsilyl groups can be simultaneously eliminated by an acid treatment.
  • Y 1 and Y 2 represent hydrogen atoms or trimethylsilyl groups.
  • the present invention provides the compound of the formula (III) (Y 1 and Y 2 are trimethylsilyl groups) crystallized in the mixed solvent comprising 5 to 10 parts by weight of acetone and 1 to 5 parts by weight of water.
  • the ratio of the compound of said formula (III) and acetone is 2: 1.
  • step 1 is carried out by reacting an equivalent of erythromycin A 9-oxime representing the above formula (II) or hydrochloride thereof with 1 to 2 equivalents of BDTF in an aprotic nonpolar organic solvent in the presence of 1 to 2 equivalents of pyridine to form erythromycin A-9-O-BDT derivative of the above formula (III)' having an oxime group, which is protected with 1, 3-benzodithiol-2-ylium (BDT) group.
  • Step 2 is carried out by reacting the resulting compound of the formula (III)' in the above step 1 with 3 to 5 equivalents of hexamethylsilazane (HMDS) in the presence of salts such as ammonium chloride, pyridine hydrochloride, pyridine, or p-toluene sulfonate to form 2'-O-, 4"-O-bitrimethylsilerythromycin A 9-O-BDT oxime derivative of the above formula (V).
  • salts such as ammonium chloride, pyridine hydrochloride, pyridine, or p-toluene sulfonate
  • a methylation of the compound of the above formula (V) at 6-OH group is carried out in an aprotic polar solvent (such as DMSO or DMF), or a mixture ratio of 1:1 of said aprotic polar solvent and TMF, or a mixture ratio of 2:2:0.3 of said aprotic solvent, TMF and a non-polar organic solvent (such as isopropylether or t-butylethylether) in an amount of 5 to 10 times that of the compound of the above formula (V) to synthesize the formula (VII).
  • an aprotic polar solvent such as DMSO or DMF
  • TMF a mixture ratio of 1:1 of said aprotic polar solvent and TMF
  • a non-polar organic solvent such as isopropylether or t-butylethylether
  • the reaction which takes about 30 minutes to 2 hours, has to be carried out in the presence of 0 to 2.5 equivalents of Et 3 N, 1 to 3 equivalents of a strong base such as NaH, alkoxide, KOH and NaOH, and 2 to 3 equivalents of a methylating agent namely methyl iodide at a temperature of -5 to 5 °C.
  • a strong base such as NaH, alkoxide, KOH and NaOH
  • the compound of the above formula (VII) of the present invention is then deprotected by using 1 to 3 equivalents of formic acid (HCO 2 H) and 4 to 8 equivalents of NaHSO 3 , Na 2 SO 3 , Na 2 S 2 O 4 , or Na 2 S 2 O 5 , and ethanol and water ratio of 1:1 in 5 to 10 parts by weight of the mixed solvent of 1:1 of ethanol and water by refluxing with heat for 4 hours.
  • HCO 2 H formic acid
  • NaHSO 3 sodium sulfonic acid
  • Na 2 SO 3 Na 2 SO 3
  • Na 2 S 2 O 4 Na 2 S 2 O 5
  • ethanol and water ratio of 1:1 in 5 to 10 parts by weight of the mixed solvent of 1:1 of ethanol and water by refluxing with heat for 4 hours.
  • BDSA which is synthesized by reacting a protective group, BDT, with a deoximizing agent such as NaHSO 3 , Na 2 SO 3 , Na 2 S 2 O 4 , or Na 2 S 2 O 5 in the presence of HCOOH, forms into its salt form, represented as the above formula (I).BDSA when joined with a 3'-N,N-dimethylamino group.
  • a deoximizing agent such as NaHSO 3 , Na 2 SO 3 , Na 2 S 2 O 4 , or Na 2 S 2 O 5 in the presence of HCOOH
  • oxime is synthesized without having any protection. Clarithromycin is synthesized as a result of a deoximization and an elimination of thrimethylsilyl group in the final step.
  • the above formula (I).BDSA is reacted with an inorganic salt such as K 2 CO 3 , Na 2 CO 3 , or KOH to remove BDSA in a neutralizing reaction and finally a pure crystal form of clarithromycin representing the above formula (I) is obtained.
  • an inorganic salt such as K 2 CO 3 , Na 2 CO 3 , or KOH
  • the neutralising reaction of step 5 is carried out by preparing the solution of the compound of the formula (I).
  • BDSA by mixing one part by weight of the said compound and 10 to 20 parts by weight of water or 5 to 10 parts by weight of water and 5 to 10 parts by weight of methanol or ethanol in a mixture ratio of 1:1, and adding 3 to 5 parts by weight of the solvent which includes 1 to 2 parts by weight of an inorganic salt to the said solution.
  • 157g(O.2 mole) of erythromycin A 9-oxyme ⁇ HCI and 5.4g(0.1 mole) of ammonium chloride were placed into a 2l flask, and 600ml of dimethylformamide were added thereto.
  • 217ml(1mole) of hexamethyldisilazane (HMDS) were slowly added to the mixture, and then stirred at a temperature of 35 to 40°C for 3 hours.
  • 30ml of water were added to the mixture, and then stirred for one hour. Thereafter, 600ml of water were further added thereto.
  • 150ml of 2N-NaOH were added thereto, and the mixture was then extracted with 600ml of dichloromethane.
  • the use of benzyl derivative as a protecting group of oxime makes the process difficult since the deprotection should be carried out by the hydrogenation reaction using the catalyst, and this deprotection is not completed on account of the catalytic poison. Furthermore, in case where the ketal derivative is used as a protecting group of oxime during the deprotection, it has the advantage that a trimethylsilyl group and an oxime may be simultaneously deprotected. However, it also has some disadvantages such as an excessive use of ketal derivative and an extended reaction time.
  • the protection of an oxime may easily be carried out in near quantitative manner by using 1,3-benzodithiol-2-ylium tetrafluoroborate (BDTF) which is simply synthesized from anthranilic acid.
  • BDTF 1,3-benzodithiol-2-ylium tetrafluoroborate
  • the said BDTF group used as a protecting group of oxime may be simultaneously removed together with trimethylsilyl group and oxime group when the deprotection is carried out under acidic conditions, it simplifies the process, and it is thus possible to obtain about 52% yield of the desired compound of formula (I) by performing this short process involving erythromycin A.
  • a BDTF group that has been used in this present invention is responsible for not only protecting oxime and allowing the selectivity, but also forming a BDSA group by reacting with deoximizing agent such as NaHSO 3 , Na 2 SO 3 , Na 2 S 2 O 4 and Na 2 S 2 O 5 and forming clarithromycin salt that can immediately be extracted from the reaction mixture as crystals to effectively indicate that the purification step can be significantly simplified.
  • deoximizing agent such as NaHSO 3 , Na 2 SO 3 , Na 2 S 2 O 4 and Na 2 S 2 O 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

An erythromycin A 9-O-benzodithiol oxime intermediate represented by the following formula (III) useful for synthesis of clarthromycin and crystalline solvate thereof:Wherein, Y1 and Y2 are independently a hydrogen atoms or trimethylsilyl groups. And, a process for the preparation of clarithromycin using the erythromycin A 9-O-benzodithiol oxime intermediate as described in the specification.

Description

FIELD OF THE INVENTION
The present invention relates to a novel process for the preparation of clarithromycin represented by formula (I), which has broad antimicrobial activity as a macrolide antibiotic agent, and a novel intermediate that can be used for its synthesis.
Figure 00010001
BACKGROUND OF THE PRIOR ART
To date, processes for the preparation of the above-mentioned compound of formula (I) are described in Korean Patent Publication Nos. 91-5898, 91-7572, 91-2142, 95-9367, and 96-434, Korean Laid-Open Patent Publication Nos. 90-18132 and 91-7953 as well as several literatures, for example, J. Antibiotics (Vol.46, No.4, 647(1993)), J. Antibiotics (Vol.46, No.7, 1163(1993), J. Antibiotics (Vol.37, No.2, 187(1984)), Heterocycles (Vol.36, No.2, 243(1993)). and J. Antibiotics (Vol.43, No. 3, 286(1990)). These processes may be summarized in the following three ways:
<Process 1>
This process comprises protecting 3'-N,N-dimethylamino group and 2'-OH group of erythromycin 9-oxime derivative, wherein an OH group is protected, with a carbobenzyloxy(Cbz) group and then methylating the hydroxyl group at the 6 position of said compound (see Korean Patent Publication Nos. 91-5898 and 91- 7572). However, this process has the disadvantages that an excess Cbz-Cl that is relatively expensive should be used, and even though the deprotection is carried out by the hydrogen reaction, this reaction is not completed on account of the catalytic poison. Further, since the methyl group of 3'-N,N-dimethylamino group of said compound has to be regenerated by methylation in the final step of the process, it has the additional disadvantages that it is difficult to perform the process, and the process is lengthy. This process may be represented by the following scheme:
Figure 00020001
<Process 2>
This process comprises protecting 3'-N,N-dimethylamino group of erythromycin 9-oxime derivative, wherein an OH group is protected, with a quaternary salt of an identical group (for example, benzyl group)(see Korean Patent Publication No.91-2142). Since the deprotection in this process is also carried out by using hydrogen as in process 1, it has the disadvantage that the reaction is not completed on account of the catalytic poison as in Process 1. This process may be represented by the following scheme:
Figure 00030001
<Process 3>
This process comprises protecting an oxime of erythromycin 9-oxime derivative with a benzyl or ketal derivative, and protecting 2'-OH group and 4'-OH group of said compound with substituted silyl groups, and then methylating a 6-OH group of said compound, and finally deprotecting a protecting group of 9-oxime and trimethylsilyl group of said 2'-O- and 4"-O- groups of said compound simultaneously in a relatively short step to obtain the desired compound (see Korean Patent Publication Nos. 95-9367 and 96-434). In this case, the 9-oxime derivative used in the trimethylsilylation of 2'-OH and 4'-OH groups should be used in the salt free form. This process is represented by the following scheme:
Figure 00030002
In accordance with the above reaction scheme, the yield of clarithromycin synthesized from an erythromycin A is about 45 to 50%. In the cases where a benzyl derivative is used to protect an oxime for the above reaction schemes, it is difficult to perform such lengthy reactions since the deprotection is carried out by using hydrogen. Another shortcoming is that the ketal derivative, which is used to protect an oxime, has to be used excessively (with about 2 to 3 equivalents) and the total reaction time is rather lengthy. Despite of such shortcoming, the ketal derivative and trimethylsilyl groups can be simultaneously eliminated by an acid treatment.
In efforts to eliminate saprophytic matters that are produced during the 3 synthetic processes mentioned above, a purification step involving precipitation of the synthesized clarithromycin is included in the above processes. However, in most cases, there is about 10 to 20 % drop in the yield. In addition, an elimination of saprophytic matters is very difficult if the saprophytic matters having similar characteristics to those of clarithromycin are present.
Accordingly, the inventors have extensively studied a new process for preparing the desired compound in order to solve the above problems of conventional methods and to increase the yield. As a result, it has been found that 1, 3-benzodithiol-2-ylium tetrafluoroborate(BDTF)(Syn. Commun., 471(1976)) represented by the following formula, which is simply synthesized from anthranilic acid, can be used as a protecting group for oxime. The present invention was made possible by means of developing a new and simple process for preparing a high yield of clarithromycin.
Figure 00040001
SUMMARY OF THE INVENTION
It is an object of this invention to provide an erythromycin A 9-0-BDT oxime intermediate represented by the following formula (III), which is useful for the synthesis of clarithromycin prepared by reacting an erythromycin A 9-oxime or hydrochloride thereof with BDTF.
Figure 00050001
Wherein, Y1 and Y2 represent hydrogen atoms or trimethylsilyl groups.
Additionally, the present invention provides the compound of the formula (III) (Y1 and Y2 are trimethylsilyl groups) crystallized in the mixed solvent comprising 5 to 10 parts by weight of acetone and 1 to 5 parts by weight of water. The ratio of the compound of said formula (III) and acetone is 2: 1.
Furthermore, it is another object of this present invention to provide a process for preparation of clarithromycin, which comprises the steps of:
  • 1) reacting an erythromycin A 9-oxime of the following formula (II) or hydrochloride thereof with 1.0 to 1.2 equivalents of 1, 3-benzothiol- 2-ylium tetrafluoroborate (BDTF) in an aprotic non polar organic solvent in the presence of 1.0 to 2.0 equivalents of pyridine to form an erythromycin A 9-O-BDT oxime derivative of the following formula (III)' having an oxime group which is protected with a benzodithiol(BDT) group, as shown in the following scheme;
    Figure 00060001
       wherein, MC is methylene dichloride,
  • 2) reacting a compound of formula (III)' synthesized in the above step 1) with 3.0 to 5.0 equivalents of hexamethyldisilazane(HMDS) in the presence of salts such as ammonium chloride, pyridine hydrochloride, pyridine or p-toluene sulfonate to form 2'-O,4"-O-bistrimethyl- silylerythromycin A 9-O-BDT oxime derivative of formula (V), as shown in the following scheme;
    Figure 00060002
  • 3) methylating a 6-OH group of the compound of formula (V) synthesized in the above step 2) with 2.0 to 3.0 equivalents of methyl iodide in an aprotic polar solvent in the presence of a strong base to form 2'-O-,4"-O-bistrimethylsilyl-6-0-methyl-erythromycin A 9-O-BDT oxime derivative of the following formula (VII) as shown in the following scheme;
    Figure 00070001
  • 4) deprotecting a compound of formula (VII) synthesized in the above step 3) to form the following formula (I) .BSDA compound as shown in the following scheme and;
    Figure 00070002
  • 5) simply stirring the formula (I) .BSDA compound synthesized from the step 4) in water or mixed solvent of water and water-miscible organic solvent (preferably methanol or ethanol), and then filtering it to form the following scheme representing the formula (I):
    Figure 00080001
    • DETAILED DESCRIPTION OF THE INVENTION
    According to the present invention, step 1 is carried out by reacting an equivalent of erythromycin A 9-oxime representing the above formula (II) or hydrochloride thereof with 1 to 2 equivalents of BDTF in an aprotic nonpolar organic solvent in the presence of 1 to 2 equivalents of pyridine to form erythromycin A-9-O-BDT derivative of the above formula (III)' having an oxime group, which is protected with 1, 3-benzodithiol-2-ylium (BDT) group.
    Step 2 is carried out by reacting the resulting compound of the formula (III)' in the above step 1 with 3 to 5 equivalents of hexamethylsilazane (HMDS) in the presence of salts such as ammonium chloride, pyridine hydrochloride, pyridine, or p-toluene sulfonate to form 2'-O-, 4"-O-bitrimethylsilerythromycin A 9-O-BDT oxime derivative of the above formula (V).
    According to the present invention, a methylation of the compound of the above formula (V) at 6-OH group is carried out in an aprotic polar solvent (such as DMSO or DMF), or a mixture ratio of 1:1 of said aprotic polar solvent and TMF, or a mixture ratio of 2:2:0.3 of said aprotic solvent, TMF and a non-polar organic solvent (such as isopropylether or t-butylethylether) in an amount of 5 to 10 times that of the compound of the above formula (V) to synthesize the formula (VII). The reaction, which takes about 30 minutes to 2 hours, has to be carried out in the presence of 0 to 2.5 equivalents of Et3N, 1 to 3 equivalents of a strong base such as NaH, alkoxide, KOH and NaOH, and 2 to 3 equivalents of a methylating agent namely methyl iodide at a temperature of -5 to 5 °C.
    The compound of the above formula (VII) of the present invention is then deprotected by using 1 to 3 equivalents of formic acid (HCO2H) and 4 to 8 equivalents of NaHSO3, Na2SO3, Na2S2O4, or Na2S2O5, and ethanol and water ratio of 1:1 in 5 to 10 parts by weight of the mixed solvent of 1:1 of ethanol and water by refluxing with heat for 4 hours. As a result, 1, 3-benzodithiole-2-sulfonic acid (BDSA) of clarithromycin representing the above formula (I) is synthesized.
    BDSA, which is synthesized by reacting a protective group, BDT, with a deoximizing agent such as NaHSO3, Na2SO3, Na2S2O4, or Na2S2O5 in the presence of HCOOH, forms into its salt form, represented as the above formula (I).BDSA when joined with a 3'-N,N-dimethylamino group. After the reaction is completed and the temperature is lowered to room temperature, the desired compound, which is crystallized in the reaction solvent, is then purified. As a result, the separation of the desired compound from the other by-products becomes very feasible. In this case, since the reaction between a BDT group and a deoximizing agent occurs first in the order of deprotection, oxime is synthesized without having any protection. Clarithromycin is synthesized as a result of a deoximization and an elimination of thrimethylsilyl group in the final step.
    According to a process of the present invention, the above formula (I).BDSA is reacted with an inorganic salt such as K2CO3, Na2CO3, or KOH to remove BDSA in a neutralizing reaction and finally a pure crystal form of clarithromycin representing the above formula (I) is obtained.
    In another embodiment, the neutralising reaction of step 5) is carried out by preparing the solution of the compound of the formula (I). BDSA by mixing one part by weight of the said compound and 10 to 20 parts by weight of water or 5 to 10 parts by weight of water and 5 to 10 parts by weight of methanol or ethanol in a mixture ratio of 1:1, and adding 3 to 5 parts by weight of the solvent which includes 1 to 2 parts by weight of an inorganic salt to the said solution.
    It is yet another object of this invention to provide another process for the preparation of clarithromycin of formula (I) by adding hexamethyldisilazane (HMDS) to erythromycin A 9-oxime representing the formula (II) or hydrochloride thereof to form 2'-O,4"-O-bistrimethylsilyl- erythromycine A 9-oxime derivative of formula (IV) in place of the above step 1), and reacting 2'-O-,4"-O-bistrimethylsilyl-erythromycin A 9-oxime derivative of formula (IV) in an aprotic organic solvent such as MC in the presence of pyridine with 1 to 2 equivalents of BDTF to form a quantitative yield of 2'-O-,4"-O-bistrimethylsiliylerythromycine A 9-O-BDT oxime derivative of formula (V) in place of the above step 2), as shown in the following scheme;
    Figure 00100001
    Once the compound of the above formula (V) is crystallized in a mixed solvent of 5 to 10 parts by weight of water and 5 to 10 parts by weight of acetone (preferably in the mixture ratio of 3:10), a crystalline solvate comprising the compound of the above formula (V) and acetone in 2:1 ratio can be obtained.
    The following are examples to illustrate the present invention in further detail but they do not limit the scope of the invention in anyway.
    EXAMPLE 1 (1) Preparation of 2'-O,4"-O-bitrimethylsilylerythromycin A 9-oxime
    157g(O.2 mole) of erythromycin A 9-oxyme · HCI and 5.4g(0.1 mole) of ammonium chloride were placed into a 2ℓ flask, and 600mℓ of dimethylformamide were added thereto. 217mℓ(1mole) of hexamethyldisilazane (HMDS) were slowly added to the mixture, and then stirred at a temperature of 35 to 40°C for 3 hours. 30mℓ of water were added to the mixture, and then stirred for one hour. Thereafter, 600mℓ of water were further added thereto. After further stirring the mixture for 30 minutes, 150mℓ of 2N-NaOH were added thereto, and the mixture was then extracted with 600mℓ of dichloromethane. An aqueous solution layer was again extracted with 2ℓ of dichloromethane. After the organic layers were combined, the mixture was washed with 200mℓ of saturated saline, solution, and then dehydrated with anhydrous MgSO4. The solvent was removed under reduced pressure to obtain 170.5g of the title compound as a foam(yield 95.4%).
    1H NMR(CDCl3) δ 0.16(s,9H, -OTMS), 0.19(s,9H, -OTMS)
    (2a) Preparation of 2'-O-,4"-O-bistrimethylsilyl- erythromycin A 9-O-BDT oxime
    8.93g(10mmole) of 2'-O-,4"-O-bistrimethylsilyl- erythromycin A 9-oxime prepared in the above 1) were dissolved in 40mℓ of dichloromethane. and 2.52g(1.05 mmole) of BDTF were then added thereto at a temperature of 20 to 25°C. 1.13mℓ(14 mmole) of pyridine were slowly added to the mixture, and then stirred for 30mins. 50mℓ of methylene dichloride and 50mℓ of water were added to the mixture, and then extracted. The organic layer was washed with saturated saline solution, dehydrated with anhydrous MgSO4, filtered, and then dried to obtain 10.25g of the title compound as a foam(yield 98.0%).
    1H NMR(CDCl3) δ 7.37(m,2H), 7.11(m,2H), 6.88(s,1H), 3.28(s.3H). 2.63(s,6H), 0.16(s,18H)
    (2b) Preparation of 2'-O-,4"-O-bistrimethylsilylerythromycin A 9-O-BDT solvate with oxime and acetone ratio of 2:1.
    30.75mℓ of water was slowly added to the desired compound of the above in the form of a foam that has already been dissolved in 102.5mℓ of acetone. The resulting solid is then placed in an ice bath, stirred for an hour, filtered and dried. As a result, 2"-O-,"4-O-bitrimethylsilyl- erythromycin A 9-O-BDT 8.95g(85.0% yield) of solvate with oxime and acetone ratio of 2:1 was obtained.
    1H-NMR(CDCl3) δ 7.37(m,2H), 7.11(m,2H), 6.88(s,mH), 3.28(s,3H), 2.63(s,6H), 2.10(s,6H), 0.16(s,18H)
    (3) Preparation of 2'-O-,4"-O-bistrimethylsilyl-6-0-methyl-erythromycin A 9- O-BDT oxime
    Before adding 10.45g(10mmole) of 2'-O,4"-O-bistrimethylsilylerythromycin A 9-O-BDT oxime prepared in the above 2) to 160mℓ of mixture of anhydrous THF, anhydrous DMSO and t-butylmethylether(2:2:0.3). 1.39mℓ of Et3N was added to the mixture. The temperature was adjusted to 0 °C. At this point, 0.98g(15mmole) of KOH and 1.25mℓ(20 mmole) of methyl iodide were added thereto. The reaction was completed after stirring the mixture for an hour. Thereafter, the mixture was sequentially extracted with 100mℓ of hexane and 100 mℓ of water. The organic layer was washed with about 10% saline solution, dehydrated with anhydrous MgSO4, and then filtered. The solvent was removed under reduced pressure to obtain 10.46g of the desired compound in the form of a foam(yield 98.8%).
    1H NMR(CDCl3) δ 7.05∼7.40(m,4H), 6.89 (s,1H), 3.31(s,3H), 2.63(s,3H), 2.22(s,6H), 0.17(s,9H), 0.09(s,9H)
    (4) Preparation of 1, 3-benzothiol-2-sulfonic acid salt
    10.60g(10mmole) of 2'-O-,4"-O-bistrimethylsilyl-6-O-methylerythromycin A 9-O-BDT oxime prepared in the above 3) were dissolved in 50mℓ of ethanol, and 50mℓ of water were then added thereto. 0.57mℓ(15mmole) of formic acid and 4.16g(40mmole) of sodium hydrogen sulfate(NaHSO3) were added to the mixture, and then refluxed with heat for 2 hours. 0.19mℓ(0.5mmole) of formic acid was added additionally to the reaction mixture and refluxed again with heat for another 2 hours. After the reaction was completed, the temperature of the reaction mixture was lowered to room temperature. The resulting solid was filtered and dried to obtain 5.80g(59.1% yield) of the desired compound.
    1H NMR(CDCl3+DMSO-d6) δ 7.18(m,2H), 7.01(m,2H), 5.61(s,1H), 5.05(d,1H), 4.89(d,1H), 4.55(d,1H), 3.97(m,2H), 3.70(m,5H), 3.40(m,2H), 3.32(s,3H), 3.02(s,8H), 2.83(dd,6H), 2.59(m,1H), 2.34(d,1H), 1.40∼1.95(m,6H), 1.37(s,3H), 1.10∼1.35(m,26H), 0.85(t,3H)
    (5) Preparation of clarithromycin
    9.82g(10mmole) of the resulting compound from the above step 4 was added to 19.64mℓ of ethanol and 49.1mℓ of water and stirred. 2.76g of K2CO3 dissolved in 49.1mℓ of water was slowly added to the mixture thereto. The resulting crystal, which was then placed in 14mg of K2CO3 dissolved in 98.2mℓ of water and stirred for 5 minutes, was filtered and dried to obtain 7.14g(95.5% yield) of the desired compound.
    1H-NMR(CDCl3) δ 5.08(d,1H), 4.93(d,1H), 4.44(d,1H), 4.02(m,1H), 3.99(s,1H), 3.78(m,2H), 3.67(d,1H), 3.33∼3.46(m,2H), 3.34(s,3H), 3.19(t,2H), 3.06(s,3H), 2.89∼3.02(m,2H), 2.89(m,1H), 2.58(m,1H), 2.40(m,2H), 2.29(s,6H), 1.93(d,1H), 1.40∼1.95(m,6H), 1.42(s,3H), 1.10∼1.35(m,26H), 0.85(t,3H)
    EXAMPLE 2
    10.33g(97.5% yield) of 2'-O-,4"-O-bitrimethylsilylerythromycin A 9-O-BDT oxime compound was obtained by the same method as in Example 1 except for 0.8g(20mmole) of 60%NaH used in the place of KOH in the step (3) of the above Example 1.
    EXAMPLE 3
    7.49g(10mmole) of erythromycin A 9-O-oxime were dissolved in 40mℓ of methylene dichloride, and 1.13mℓ (14mmole) of pyridine were added thereto. 2.64g(11mmole) of BDTF was added portion-wise to the mixture at room temperature, and then stirred at the same temperature for 30 minutes. After the reaction was completed, 40mℓ of methylene dichloride and 60mℓ of water were added to the mixture, and then extracted. The organic layer was washed with 10% saline solution, dehydrated with anhydrous MgSO4, and then filtered. The solvent was removed under reduced pressure to obtain 8.76g of the desired compound in the form of a foam(yield 97.2%). The rest of the procedure was performed in the same manner as in the step (2) of the above Example 1.
    1H NMR(CDCl3) δ 7.30(m,2H), 7.13(m,2H), 6.87(s,1H), 3.30(s,3H), 2.50(s,6H)
    EXAMPLE 4
    9.01g(10 mmole) of erythromycin A 9-0-BDT oxime prepared in the step (2) of the above Example 1 and Examples 3 and 4, and 0.8g(15 mmole) of ammonium chloride were added to 27mℓ of dimethylformamide. 8.44mℓ (40mmole) of hexamethyldisilazane(HMDS) were slowly added to the mixture, and then stirred at a temperature of 40 to 50°C for 5 hours. The mixture was sequentially extracted with 60mℓ of water and 60mℓ of dichloromethane, and the aqueous layer was again extracted with 20mℓ of dichloromethane. The organic layers were combined, washed with 20mℓ of saturated saline solution, and then dehydrated with anhydrous MgSO4. The solvent was removed under reduced pressure to obtain 9.53g of the desired compound in the form of foam (yield 91.2%). The rest of the procedure was performed in the same manner as in the step (3) of the above Example 1.
    EXAMPLE 5
    5.67g(57.7% yield) of 1, 3-benzodithiol-2-sulfonic acid was obtained by the same method as in Example 1 except that 8.2g(40mmole) of Na2S2O4 used in the place of NaHSO3 in the step (4) of the above Example 1.
    EXAMPLE 6
    5.49g(55.9% yield) of 1,3-benzodithiol-2-sulfonic acid was obtained by the same method as in Example 1 except that 7.84g(40mmole) of Na2S2O5 used in the place of NaHSO3 in the step (4) of the above Example 1.
    EXAMPLE 7
    5.62g(57.2% yield) of 1, 3-benzodithiol-2-sulfonic acid was obtained by the same method as in Example 1 except that 5.04g(40mmole) of Na2S2O3 used in the place of NaHSO3 in the step (4) of the above Example 1.
    The following are the effects of this present invention:
    First of all, in the prior art, the use of benzyl derivative as a protecting group of oxime makes the process difficult since the deprotection should be carried out by the hydrogenation reaction using the catalyst, and this deprotection is not completed on account of the catalytic poison. Furthermore, in case where the ketal derivative is used as a protecting group of oxime during the deprotection, it has the advantage that a trimethylsilyl group and an oxime may be simultaneously deprotected. However, it also has some disadvantages such as an excessive use of ketal derivative and an extended reaction time. However, according to the present invention, the protection of an oxime may easily be carried out in near quantitative manner by using 1,3-benzodithiol-2-ylium tetrafluoroborate (BDTF) which is simply synthesized from anthranilic acid. Furthermore, since the said BDTF group used as a protecting group of oxime may be simultaneously removed together with trimethylsilyl group and oxime group when the deprotection is carried out under acidic conditions, it simplifies the process, and it is thus possible to obtain about 52% yield of the desired compound of formula (I) by performing this short process involving erythromycin A.
    Secondly, in the prior art, since a step involving crystallization in ethanol was necessary after the deprotection for the purification of the purest form of clarithromycin, about 10 to 20% drop in the yield has incurred as a result. However, in the present invention, the formation of the salts by joining the resulting clarithromycin from the deprotection and the resulting BDSA from the reaction between a protective group and a deoximizing agent is carried out and cooled at room temperature for an immediate crystallization of the salts in the reaction mixture for a separation of a purest form of crystals.
    Consequently, once the salts are eliminated by neutralization, clarithromycin having a high purity and yield can be obtained and the purification step can be significantly simplified.
    Thirdly, while a protective group of oxime in the prior art has only protected oxime and allowed a selectivity for introduction of a methyl group, a BDTF group that has been used in this present invention is responsible for not only protecting oxime and allowing the selectivity, but also forming a BDSA group by reacting with deoximizing agent such as NaHSO3 , Na2SO3 , Na2S2O4 and Na2S2O5 and forming clarithromycin salt that can immediately be extracted from the reaction mixture as crystals to effectively indicate that the purification step can be significantly simplified.

    Claims (8)

    1. An erythromycin A 9-O-benzodithide oxime intermediate useful for synthesis of clarthromycin prepared by reacting erythromycin A 9-Oxime or hydrochloride thereof with 1,3-benzodithiol-2-ylium tetrafluoroborate (BDTF) represented by formula (III);
      Figure 00160001
         wherein, Y1 and Y2 are hydrogen atoms or trimethylsilyl groups.
    2. The intermediate according to Claim 1, wherein a compound of the above formula (III) (Y1 and Y2 are trimethylsilyl groups) is crystallized in the mixed solvent of 5 to 10 parts by weight of acetone and 1 to 5 parts by weight of water, and the ratio of the resulting crystalline solvate comprising the compound of said formula and acetone in 2:1.
    3. A process for the preparation of clarithromycin of formula (I), which comprises the steps of:
      1) reacting an erythromycin A 9-oxime of the following formula (II) or hydrochloride thereof with 1.0 to 1.2 equivalents of 1,3-benzodithiol-2-ylium tetrafluoroborate (BDTF) in an aprotic non polar organic solvent in the presence of 1.0 to 2.0 equivalents of pyridine to synthesize an erythromycin A 9-O-BDT oxime derivative of formula (III)' having an oxime group which is protected with 1,3-benzodithiole (BDT) group, as shown in the following scheme;
      Figure 00170001
         wherein, MC is methylene dichloride,
      2) reacting a compound of formula (III)' synthesized in the above step 1) with 3.0 to 5.0 equivalents of hexamethyldisilazane (HMDS) in the presence of salts such as ammonium chloride, pyridine hydrochloride, pyridine or p-toluene sulfonate to form 2'-O-,4"-O-bistrimethylsilylerythromycin A 9-O-BDT derivative of formula (V), as shown in the following scheme;
      Figure 00170002
      3) methylating a 6-OH group of the compound of formula (V) synthesized in the above step 2) with 2.0 to 3.0 equivalents of methyl iodide in an aprotic polar solvent in the presence of strong base to form 2'-O,-4"-O-bistrimethylsilyl-6-O-methyl-erythromycin A 9-O-BDT oxime derivative of formula (VII) as shown in the following scheme;
      Figure 00180001
      4) deprotecting the compound of formula (VII) synthesized in the above step 3) to form the following formula (I) .BDSA and;
      Figure 00180002
      5) stirring the compound of formula (I). BDSA synthesized in the above step 4) in water or a mixture of water and water-miscible organic solvent in the presence of an inorganic salt and then filtering it to form a clarithromycin representing the following formula (I);
      Figure 00190001
    4. The process according to Claim 3, which comprises the steps of adding hexamethyldisilazane (HMDS) to erythromycin A 9-oxime or hydrochloride thereof to form 2'-O-4"-O-bistrimethylsilyl- erythromycin A 9-oxime derivative of the following formula (IV) in place of the above step 1), and reacting 2'-O'-4"-O-bistrimethylsilyl-erythromycin A 9-oxime derivative of said formula (IV) in an aprotic organic solvent in the presence of pyridine with a BDTF to form 2'-O'-4"-O-bistrimethylsilyl-erythromycin A 9-O-BDT-oxime derivative of formula (V) in place of the above step 2), as shown in the following scheme:
      Figure 00190002
    5. The process according to Claim 3, wherein the methylation of the above step 3) is carried out at a reaction temperature of -5 to 5°C by using an aprotic polar solvent such as DMF or DMSO, a mixture ratio of 1:1 of said aprotic polar solvent and THF, or a mixture of 2:2:0.3 of said aprotic polar solvent, THF and a non-polar organic solvent such as isoproplyether or t-butylmethylether, which is used 5 to 10 times the compound of formula (V), with 1.0 to 3.0 equivalents of a strong base such as KOH, alkoxide and NaH, and 2.0 to 3.0 equivalents of methyl iodide as a methylating agent in the presence of 0 to 2.5 equivalents of Et3N for 30 minutes to 2 hours.
    6. The process according to Claim 3, wherein the miscible organic solvent in the above step 5) is methanol or ethanol.
    7. The process according to Claim 3, wherein the deprotection of the above step 4) is carried out by using 1.0 to 3.0 equivalents of formic acid and 4.0 to 8.0 equivalents of NaHSO3, Na2S2O4, Na2S2O5 or Na2SO3 in 5 to 10 parts by weight of the mixture ratio of 1:1 of ethanol and water, and cooled at room temperature before being crystallized.
    8. The process according to Claim 3, wherein the neutralizing reaction of the above step 5) is carried out by preparing the solution of the compound of the above formula (I). BDSA by mixing one part by weight of said compound and 10 to 20 parts by weight of water or 5 to 10 parts by weight of water and 5 to 10 parts by weight of methanol or ethanol in a mixture ratio of 1:1, and adding 3 to 5 parts by weight of the solvent which includes 1 to 2 parts by weight of an inorganic salt to said solution.
    EP99958490A 1998-11-24 1999-11-24 Novel intermediates, process for preparing macrolide antibiotic agent therefrom Expired - Lifetime EP1133511B1 (en)

    Applications Claiming Priority (5)

    Application Number Priority Date Filing Date Title
    KR19980050425 1998-11-24
    KR9850425 1998-11-24
    KR9950802 1999-11-16
    KR1019990050802A KR100317907B1 (en) 1998-11-24 1999-11-16 Novel Intermediates, process for preparing macrolide antibiotic agent therefrom
    PCT/KR1999/000708 WO2000031099A1 (en) 1998-11-24 1999-11-24 Novel intermediates, process for preparing macrolide antibiotic agent therefrom

    Publications (2)

    Publication Number Publication Date
    EP1133511A1 EP1133511A1 (en) 2001-09-19
    EP1133511B1 true EP1133511B1 (en) 2003-03-12

    Family

    ID=26634358

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP99958490A Expired - Lifetime EP1133511B1 (en) 1998-11-24 1999-11-24 Novel intermediates, process for preparing macrolide antibiotic agent therefrom

    Country Status (21)

    Country Link
    US (1) US6600025B1 (en)
    EP (1) EP1133511B1 (en)
    JP (1) JP3848837B2 (en)
    KR (1) KR100317907B1 (en)
    CN (1) CN1354753A (en)
    AT (1) ATE234321T1 (en)
    AU (1) AU751874B2 (en)
    BR (1) BR9915646A (en)
    CA (1) CA2352162A1 (en)
    CZ (1) CZ20011803A3 (en)
    DE (1) DE69905935T2 (en)
    DK (1) DK1133511T3 (en)
    ES (1) ES2190275T3 (en)
    HU (1) HUP0104600A3 (en)
    IL (1) IL143331A0 (en)
    MX (1) MXPA01005248A (en)
    PL (1) PL348607A1 (en)
    PT (1) PT1133511E (en)
    RU (1) RU2208615C2 (en)
    TR (1) TR200101474T2 (en)
    WO (1) WO2000031099A1 (en)

    Families Citing this family (16)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2004080391A2 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
    ES2221807B1 (en) * 2003-06-24 2005-12-16 Ercros Industrial, S.A. A PROCEDURE FOR OBTAINING CLARITROMYCIN.
    US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
    US7582611B2 (en) * 2005-05-24 2009-09-01 Pfizer Inc. Motilide compounds
    US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
    US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
    US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
    WO2010048600A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
    US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
    WO2011032052A1 (en) 2009-09-10 2011-03-17 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
    DK2550286T3 (en) * 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
    EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
    WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
    RU2658050C2 (en) 2012-03-27 2018-06-19 Семпра Фармасьютикалз, Инк. Parenteral formulations for administering macrolide antibiotics
    AU2014239959A1 (en) 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
    US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

    Family Cites Families (7)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US5872229A (en) * 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
    US5719272A (en) * 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
    US5864023A (en) * 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
    US5929219A (en) * 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
    IL136089A0 (en) * 1997-12-01 2001-05-20 Abbott Lab Chemical synthesis of 6-0-alkyl erythromycin c
    WO1999032500A2 (en) * 1997-12-22 1999-07-01 Biochemie S.A. Intermediates in macrolide production
    WO1999040097A1 (en) * 1998-02-04 1999-08-12 Teva Pharmaceutical Industries Ltd. Process for making clarithromycin

    Also Published As

    Publication number Publication date
    IL143331A0 (en) 2002-04-21
    KR100317907B1 (en) 2001-12-24
    BR9915646A (en) 2001-08-07
    WO2000031099A1 (en) 2000-06-02
    PL348607A1 (en) 2002-06-03
    MXPA01005248A (en) 2003-08-19
    HUP0104600A2 (en) 2002-03-28
    AU751874B2 (en) 2002-08-29
    ES2190275T3 (en) 2003-07-16
    AU1584700A (en) 2000-06-13
    PT1133511E (en) 2003-06-30
    CA2352162A1 (en) 2000-06-02
    JP2002530423A (en) 2002-09-17
    RU2208615C2 (en) 2003-07-20
    DK1133511T3 (en) 2003-07-14
    EP1133511A1 (en) 2001-09-19
    TR200101474T2 (en) 2001-12-21
    DE69905935T2 (en) 2003-09-04
    US6600025B1 (en) 2003-07-29
    ATE234321T1 (en) 2003-03-15
    HUP0104600A3 (en) 2003-12-29
    JP3848837B2 (en) 2006-11-22
    DE69905935D1 (en) 2003-04-17
    CN1354753A (en) 2002-06-19
    KR20000057013A (en) 2000-09-15
    CZ20011803A3 (en) 2001-10-17

    Similar Documents

    Publication Publication Date Title
    EP1133511B1 (en) Novel intermediates, process for preparing macrolide antibiotic agent therefrom
    EP0180415B1 (en) A 6-0-methylerythromycin A derivative
    EP0195960B1 (en) Method for selective methylation of erythromycin a derivatives
    JPS6328438B2 (en)
    EP0421081A1 (en) Process for the preparation of 23-(C1-C6 alkyloxime)LL-F28249 compounds
    JP3983803B2 (en) Production of anthracycline antibiotics
    EP0080819B1 (en) 11-0-alkylerythromycin a derivatives
    JP4888840B2 (en) Process for the preparation of pyrazole-O-glycoside derivatives and novel intermediates of said process
    KR100206357B1 (en) A process for the glycosylation of colchicine derivatives and product thereof
    CZ191398A3 (en) Process for preparing 9,11{beta}epoxy-steroids
    JPS5827798B2 (en) Intermediates for new antibacterial agents
    WO1991003460A1 (en) New route of synthesis for tertiary alkyl esters
    PL187648B1 (en) Method of obtaining a derivative of deoxyuridine
    JPH031317B2 (en)
    JP3258914B2 (en) Method for producing erythromycin derivative
    KR100361397B1 (en) Process for producing clarithromycin using erythromycin a 9-o-tropyloxime derivatives
    WO2004007518A1 (en) Erythromycin a 9-o-pseudosaccharinyloxime derivatives and process for the preparation of clarithromycin using the same
    EP1408047B1 (en) Process for preparation of erythromycin compounds
    JPH11512114A (en) Preparation of disubstituted thiazoles
    JP2504934B2 (en) 1,6,7-Triacylforskolin derivative
    JP5192807B2 (en) Stable crystals of protected pseudouridine
    CA2261106C (en) Process for preparing erythromycin derivative, such as roxithromycin, from the corresponding oxime
    JPH07252293A (en) Deoxyribonucleoside derivative and its production
    JP3978006B2 (en) Method for producing erythromycin derivative
    WO2006097121A1 (en) Method for producing biphenyl-tetrazole compounds

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 20010612

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AX Request for extension of the european patent

    Free format text: MK;SI

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20030312

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

    Effective date: 20030312

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20030312

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20030312

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20030312

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20030312

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20030312

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: ISLER & PEDRAZZINI AG

    Ref country code: CH

    Ref legal event code: EP

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REF Corresponds to:

    Ref document number: 69905935

    Country of ref document: DE

    Date of ref document: 20030417

    Kind code of ref document: P

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: TRGR

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Free format text: AVAILABILITY OF NATIONAL TRANSLATION

    Effective date: 20030507

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2190275

    Country of ref document: ES

    Kind code of ref document: T3

    NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031124

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031124

    Ref country code: CY

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20031124

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20031130

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    EN Fr: translation not filed
    26N No opposition filed

    Effective date: 20031215

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MM4A

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20061116

    Year of fee payment: 8

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20061122

    Year of fee payment: 8

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: PT

    Payment date: 20061124

    Year of fee payment: 8

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: SE

    Payment date: 20061128

    Year of fee payment: 8

    Ref country code: DK

    Payment date: 20061128

    Year of fee payment: 8

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: ES

    Payment date: 20061129

    Year of fee payment: 8

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: CH

    Payment date: 20061130

    Year of fee payment: 8

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PCAR

    Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: MM4A

    Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

    Effective date: 20080526

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EBP

    EUG Se: european patent has lapsed
    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20071124

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20071130

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20071130

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20080526

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20071125

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20071130

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20080603

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20071124

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20071126

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20071126